Tasquinimod

History

Collaborative studies by laboratories at Johns Hopkins School of Medicine and Active Biotech Research AB identified tasquinimod as the lead agent for developing a treatment for prostate cancer. Tasquinimod was one of several second-generation quinoline-3-carboxamide variants synthesized using the drug roquinimex as a starting point, and it performed well in pre-clinical studies of cancer models.

In April 2011, Ipsen and Active Biotech entered into a broad partnership for the co-development of tasquinimod for the treatment of cancer. Active Biotech granted Ipsen exclusive rights to commercialize tasquinimod worldwide, except in North and South America and Japan where Active Biotech retained all commercial and marketing rights.

Mechanism of action

Tasquinimod is a novel small-molecule inhibitor that targets the tumor microenvironment by controlling the accumulation and immunosuppressive, pro-angiogenic and pro-metastatic functions of regulatory myeloid cells (also called myeloid-derived suppressor cells). It binds to and inhibits the interactions of S100A9, an immunomodulatory protein that promotes tumor development, influences suppressive and pro-angiogenic cells in the tumor microenvironment, and participates in the establishment of pre-metastatic niches.

Tasquinimod may also target the tumor microenvironment by suppressing the tumor hypoxic response, in which genes involved in the adaptation and survival of cells during hypoxia are induced. Tasquinimod reduces tumor angiogenesis; but its anti-angiogenic effects do not appear to be linked to vascular endothelial growth factor (VEGF) neutralization or VEGF receptor tyrosine kinase inhibition.

Clinical studies

A randomized, double-blind, placebo-controlled phase II study comparing tasquinimod with placebo in 206 men with metastatic CRPC was completed in 2009. The primary endpoint in the trial was to show a difference in the number of patients with disease progression at 6 months. The proportion of patients who were disease progression-free after 6 months was 69% for patients treated with tasquinimod versus 37% for placebo-treated patients (p

Analysis of up to 3 years of safety data from phase II studies showed that treatment-related adverse events were mild to moderate, manageable and less frequent after 2 months of therapy. Adverse events observed included gastrointestinal disorders, fatigue, musculoskeletal pain as well as elevations of some laboratory parameters.

A phase III randomized controlled trial called 10TASQ10 to confirm tasquinimod's effect on disease progression is ongoing. More than 1,200 patients with asymptomatic to mildly symptomatic metastatic CRPC were successfully enrolled in the study, as planned in the clinical protocol.

References

References

1. (October 2009). "Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer". British Journal of Cancer.
2. (December 2006). "Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer". The Prostate.
3. (February 2013). "Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment". Cancer Research.
4. (2012). "S100A9 interaction with TLR4 promotes tumor growth". PLOS ONE.
5. (June 2012). "Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050)". The Prostate.
6. {{ClinicalTrialsGov. NCT01234311. A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
7. (10 December 2012). "Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer". Active Biotech.
8. (October 2011). "Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer". Journal of Clinical Oncology.
9. (June 2012). "Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial.".
10. (April 2009). "Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides". PLOS Biology.
11. (October 2010). "The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer". Expert Opinion on Investigational Drugs.
12. (May 2007). "The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts". The Prostate.
13. (May 2010). "Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors". Molecular Cancer.
14. (18 April 2011). "Active Biotech and Ipsen enter into a broad partnership for the co- development and commercialization of TASQ in". Active Biotech.
15. (August 2008). "The role of myeloid cells in the promotion of tumour angiogenesis". Nature Reviews. Cancer.
16. (October 2008). "RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis". Carcinogenesis.
17. (December 2006). "S100 chemokines mediate bookmarking of premetastatic niches". Nature Cell Biology.
18. (October 2008). "Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells". Journal of Immunology.
19. NCT01743469. A Study With Tasquinimod Treating Patients in Four Independent Cohorts of Hepatocellular, Ovarian, Renal Cell and Gastric Cancers